Tuesday, May 22, 2018

Investor Ideas ‘Potcast’; #Cannabis News and Stocks on the Move; (TSX: $ACB.TO), (CSE: $ATT.C), (TSXV: $ICC.V), (TSX: $TGOD.TO)

Investor Ideas ‘Potcast’; #Cannabis News and Stocks on the Move; (TSX: $ACB.TO), (CSE: $ATT.C), (TSXV: $ICC.V), (TSX: $TGOD.TO) 

New Frontier Data Adjusts CA Projections 

Pt. Roberts, WA; Delta, BC – May 22, 2018 (Investorideas.com Newswire) www.Investorideas.com, a global news source covering leading sectors including marijuana and hemp stocks and its “potcast’ site, www.potcasts.ca  release today’s edition of
its new series, Investorideas.com potcasts - cannabis news and stocks to watch plus insight from thought leaders and experts.

Listen to the podcast:

Today’s podcast overview/transcript:

Good afternoon and welcome to Investorideas.com  potcasts-  following cannabis news, stocks to watch as well as insight from thought leaders and experts . Today we are looking at announcements from Aurora Cannabis Inc. (TSX : ACB , OTCQB: ACBFF), Abattis Bioceuticals Corp. (CSE: ATT ,OTC: ATTBF), ICC Labs Inc. (TSX-V: ICC )  and The Green Organic Dutchman Holdings Ltd. (TSX: TGOD).  

Before the other announcements however we look at New Frontier Data, the authority in data, analytics and business intelligence in the cannabis industry, has refined the state market projections for California in light of the state’s recent lower than expected cannabis excise-tax revenues for the first quarter of 2018. The state collected $33.6 million between January 1 and March 31, which put them significantly below the original of $175 million within the first six months of 2018. New Frontier Data has reduced the latest sales projections for 2018 from $3.8 billion to $1.9 billion. And by 2025, our forecast for total California sales to be $4.72 billion instead our previously projected $6.7 billion.
New Frontier Data looked at two key aspects of the California market; their analysts redefined what a legal medical patient is and lowered the conversation rate for illicit market consumers transitioning to legal adult-use market consumers.

Next looking at Aurora Cannabis Inc. and CTT Pharmaceutical Holdings Inc. who today announced that Aurora is acquiring an initial 9.14% ownership interest in CTT via way of a non-brokered private placement in the form of a US$1 million 5% convertible debenture. The agreement includes an issuance of warrants enabling Aurora to increase ownership to 42.5%.

CTT will now provide Aurora with global exclusivity to develop, manufacture and market CTT’s novel oral thin films wafers. The companies will work jointly towards obtaining Health Canada approval for introduction of the new products on the Canadian market, as well as obtaining commercial access to other international jurisdictions in which Aurora is active.

A little about CTT; they’re an Ontario based global leader in the development of dose specific fast dissolving oral thin film wafers that provide a dose specific, smoke-free delivery of medical cannabis or other active ingredients. CTT’s oral thin film wafer is made from FDA approved non-medical ingredients used in several pharmaceutical formulations and provides the effective oral delivery of a specific dose with rapid onset of action within 5-10 minutes after dosing. Clinical research undertaken by CTT indicates the oral wafer delivery of THC into the blood steam was approximately 40% quicker compared to edible form factors, as well as resulted in approximately 28% more THC in the blood stream at peak bioavailability levels.

Abattis Bioceuticals Corp. announced the addition of three new vaporizers to its product line today. Since the Company’s acquisition of Green Tree Therapeutics earlier this year, Abattis has been working to expand its retail presence and product line and is now ready to release its first three vaporizers, the VB-1, VB-2 and the KB-1.

”We believe that the future of the cannabis vaporizer market is in branding, concentrates and ancillary products,” stated Rob Abenante, President and CEO of Abattis. “Users in the retail space are looking for functional, discreet and durable products and we feel that our new titillating product line will meet all these demands. In this, we are excited to take another step towards our goal of becoming a complete one-stop provider of downstream cannabis solutions,” added Mr. Abenante.

ICC Labs Inc. announced that it has signed a letter of intent with CanPharma GmbH a licensed importer and wholesaler of narcotics in the Federal Republic of Germany.

Through its relationship with CanPharma, ICC Labs intends to export to Germany CBD isolate, oils and other derivatives, as well as various medicinal THC cannabis products, including dried flowers and cannabis extracts from their facilities in Uruguay and Colombia. The export arrangement for THC cannabis products is subject to receipt of the requisite regulatory approvals and the negotiation of definitive agreements by the end of second quarter this year.

Germany, with a population of 83 million people, €3.3 trillion in GDP and €320 billion of healthcare expenditure, is home to Europe’s largest medical cannabis market. Germany is already leading the way among European countries with a market value of US$11.9 billion.(1)

Finally looking at The Green Organic Dutchman Holdings Ltd. who announced that the Company has entered into an exclusive agreement with CBx Enterprises LLC for the licensing of the Evolab and CBx Sciences brands and proprietary technologies and formulations within Canada and other international jurisdictions outside of the USA.

Based in Colorado, the CBx team brings decades of experience developing and marketing a diverse array of unique, first-to-market medical and recreational cannabis products. The licensing arrangement will immediately expand TGOD’s product and technology portfolio, and position the Company for the successful development of new products as Canadian and global product requirements and standards rapidly evolve.

Evolab is a top cannabinoid vaporization brand that has gained significant market share through the creation of highly differentiated products in a very competitive and saturated market. Evolab’s proprietary technologies and industry-leading extraction efficiencies allow for the derivation of pharmaceutical-grade cannabinoid oils and strain-specific terpenes without the use of any harmful solvents or cutting-agents. These technologies and formulations lead to the creation of much cleaner and safer full-plant oils for vaporization without the introduction of chemicals commonly found in the e-vape industry.

Investor ideas reminds all listeners to read our disclaimers and disclosures
on the Investorideas.com  website and this podcast is not an endorsement to
buy products or services or securities. Investors are reminded all
investment involves risk and possible loss of investment

Subscribe to the new cannabis podcast series:

To hear more Investorideas.com podcasts visit: http://www.investorideas.com/Audio/.
Investorideas.com podcasts are also available on iTunes, Google Play Music, Stitcher and Tunein.

About Investorideas.com - News that Inspires Big Ideas
Investorideas.com is a meeting place for global investors, featuring news, stock directories, video, company profiles, interviews and more in leading sectors.  
Investorideas.com cannabis/marijuana and hemp content now includes http://cannabisstocknews.blogspot.com on Blogger.com: the Investorideas.com news and stock directory pages, a cannabis investor group on Linkedin.com , the 420 Cannabis Investor ideas www.420cannabisinvestorideas.com, and the new AI site  Global Cannabis Investing at www.Globalcannabisinvesting.com

Disclaimer/Disclosure: Investorideas.com is a digital publisher of third party sourced news, articles and equity research as well as creates original content, including video, interviews and articles. Original content created by investorideas is protected by copyright laws other than syndication rights. Our site does not make recommendations for purchases or sale of stocks, services or products. Nothing on our sites should be construed as an offer or solicitation to buy or sell products or securities. All investment involves risk and possible loss of investment. This site is currently compensated for news publication and distribution, social media and marketing, content creation and more. Contact each company directly regarding content and press release questions. Disclosure is posted for each compensated news release, content published /created if required but otherwise the news was not compensated for and was published for the sole interest of our readers and followers. More disclaimer info: http://www.investorideas.com/About/Disclaimer.asp.
Additional info regarding BC Residents and global Investors: Effective September 15 2008 - all BC investors should review all OTC and Pink sheet listed companies for adherence in new disclosure filings and filing appropriate documents with Sedar. Read for more info: http://www.bcsc.bc.ca/release.aspx?id=6894.  Global investors must adhere to regulations of each country.

To sponsor this podcast or be a guest

Contact Investorideas.com


Marijuana / Hemp Stocks at Cannabisinvestorideas.com and Investorideas.com

Like Marijuana / Hemp Stocks? View our Marijuana / Hemp Stocks Directory
Also check out our AI blog Global Cannabis Investing - features Investor Ideas Cannabis news

No comments:

Post a Comment